+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ralinepag"

Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028 - Product Thumbnail Image

Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

  • Report
  • May 2023
  • 190 Pages
  • Global
From
Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • January 2024
  • 250 Pages
  • Global
From
ralinepag - Product Thumbnail Image

ralinepag

  • Report
  • October 2018
  • 15 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

The Ralinepag market is a segment of the cardiovascular drug market that focuses on the development and commercialization of drugs for the treatment of pulmonary arterial hypertension (PAH). Ralinepag is a selective prostacyclin receptor agonist that is used to reduce pulmonary vascular resistance and improve exercise capacity in patients with PAH. It is also used to reduce the risk of hospitalization due to worsening PAH. The Ralinepag market is expected to grow due to the increasing prevalence of PAH and the increasing demand for effective treatments. The Ralinepag market is highly competitive, with several major players. These include Actelion Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, and United Therapeutics. These companies are engaged in the development and commercialization of Ralinepag and other PAH treatments. Show Less Read more